134523-03-8

• 常用中文名：阿托伐他汀钙
• 常用英文名：Atorvastatin calcium
• CAS号：134523-03-8
• 分子式：C₆₆H₆₈CaF₂N₄O₁₀
• 分子量：1155.342
• 相关类别： 原料药 循环系统用药 调节血脂药
• 发布时间：2018-03-11 08:00:00
• 更新时间：2026-07-05 22:45:32
• 原料药。用于调节血脂、抗动脉粥样硬化。

名称

• 中文名: 阿托伐他汀钙
• 英文名: Atorvastatin calcium
• 中文别名: 阿托钙; 阿伐他汀钙 只有钙盐的; 阿托伐他汀钙晶型Ⅷ; 阿托伐他汀钙(无定形的); R.(R. .R:)-2-(4氟苯基)-B.0二羟基-5-(1-甲基乙基):3-茎基[(苤胺基)羟基)-1H-吡咯-1-唐酸钙盐(无定型); (3R,5R)-7-(2-(4-氟苯基)-5-异丙基-3-苯基-4-(苯基氨甲酰)-1H-吡咯-1-基)-3,5-二羟基庚酸钙盐; 阿托伐他汀钙L4(API); R,(R﹡,R﹡)]-2-(4-氟苯基 )-Β,Α-二羟基-5-(1-甲基乙基)-3-苯基-[(苯胺基)-羟基]-1H-吡咯-1-庚酸钙盐; 阿托伐他汀钙 ATORVASTATIN CALCIUM; ATORVASTATIN HEMICALCIUM SALT,HMG-COA REDUCTASE抑制剂; Atorvastatin hemicalcium salt (Synonyms: 阿托伐他汀钙; 阿伐他汀 产品类别; 阿托伐司他汀钙; A137-阿托伐他汀钙; [R,(R﹡,R﹡)]-2-(4-氟苯基 )-Β,Α-二羟基-5-(1-甲基乙基)-3-苯基-[(苯胺基)-羟基]-1H-吡咯-1-庚酸钙盐(2:1)(结晶型); 阿托伐他汀中间L-4; 阿托伐他汀非结晶型 L-5; 阿托伐他汀半钙; LIPITOR|||ATORVASTATIN HEMICALCIUM|||ATORVASTATIN CALCIUM|||CI-981|||阿托伐他汀钙|||SORTIS; 阿托伐他汀钙(FORM 1); 阿托伐他汀钙晶型I; 阿托伐他汀钙无水物; 7-[2-(4-氟苯基)-3-苯基-4-(苯胺基甲酰基)-5-(2-丙基)吡咯-1-基]-3,5-二羟基庚酸钙; 抑制剂Atorvastatin Hemicalcium; 阿托伐他汀钙原料药; 阿托伐他汀钙(标准品); 阿托伐他汀钙无定型; 阿托伐他汀钙对照品; [R,(R﹡,R﹡)]-2-(4-氟苯基 )-Β,Α-二羟基-5-(1-甲基乙基)-3-苯基-[(苯胺基)-羟基]-1H-吡咯-1-庚酸钙盐(无定型); R,(R. .R. )-2-(4氟苯基)_B,.0-二羟基-5-(1-甲基乙基)3-苯基[(苤胺基)经基H-吡路1.康酸钙盐(2:1)三水(结晶型); (3R,5R)-7-(2-(4-氟苯基)-5-异丙基-3-苯基-4-(苯基氨甲酰)-1H-吡咯-1-基)-3,5-二羟基庚酸钙盐(2:1); 阿托伐他汀钙,10 MM DMSO 溶液; 阿托伐司他丁钙; HMG-COA REDUCTASE抑制剂(ATORVASTATIN HEMICALCIUM SALT); Atorvastatin hemicalcium salt 活性化合物; [R,(R﹡,R﹡)]-2-(4-氟苯基 )-Β,Α-二羟基-5-(1-甲基乙基)-3-苯基-[(苯胺基)-羟基]-1H-吡咯-1-庚酸钙盐(2:1); 阿伐他汀钙; [R,(R﹡,R﹡)]-2-(4-氟苯基 )-Β,Α-二羟基-5-(1-甲基乙基)-3-苯基-[(苯胺基)-羟基]-1H-吡咯-1-庚酸钙盐(2:1)三水(结晶型)
• 英文别名: AtorvastatinCaliciumsalt; Atorvastatin (hemicalcium salt); Bis[(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcbamoyl-1-pyrrolyl]-3,5-dihydroxyhtanoic acid] calcium salt; calcium bis{(3R,5R)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate}; 3R ,5R )-7-[2-(4-Fluorophenyl)-5-Isopropyl-3-Phenyl-4-(Pheynylcbamoyl) Pyrrol-1-yl]-3 ,5 ydrohtanoic Acid, calcium salt (2:1) Trihydrate; Lipibec; Atorvastatin, Calcium Salt - - Calbiochem; (bR,dR)-2-(4-Fluorophenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-htanoic Acid; Atorvastatin hemicalcium salt; (R,R)-2-(4-Fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-htanoicacidhemicalciumsalt; Bis[(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-yl]-3,5-dihydroxyhtanoic acid] calcium salt; Atorvastatin CalciuM Trihydrate; ATORVASTATIN CALCIUM MM(CRM STANDD); Atorvastatin caL; Atorvastatin HeMicalciuM; Sortis; (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3; (βR,δR)-2-(4-Fluorophenyl)-β,δ-dihydroxy-5-(1-Methylethyl)-3-phenyl-4-[(phenylaMino)carbonyl]-1H-pyrrole-1-htanoic Acid CalciuM Salt; t trihydrate; ATORVASTATINCALCUIM; Lipitor; atorvastatine calciuM salt; CalciuM (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcbaMoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyhtanoate; cium saL; [R-(R*, R*)]-7-[2-(4-Fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylaminocarbonyl)-1H-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid calcium salt; 3S,5S-Atorvastatin; Atorvastatinecalcium; ATORVASTATIN CALCIUM SALT; 1h-pyrrole-1-htanoicacid,beta,delta-dihydroxy-2-(4-fluorophenyl)-5-(1-methy; Pyrrole-1-htanoic acid; (3R ,5R )-7-[2-(4-Fluorophenyl)-5-Isopropyl-3-Phenyl-4-(Pheynylcarbamoyl)Pyrrol-1-yl]-3,5-Dihydroheptanoic Acid,calcium salt (2:1) Trihydrate; Calcium of atorvastatin; (3R,5R)-7-(2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-(PHENYLCBAMOYL)-1H-PYRROL-1-YL)-3,5-DIHYDROXYHTANOIC ACID CALCIUM; Bis[(3R,5R)-3,5-dihydroxy-7-[2-(1-methylethyl)-3-[(phenylamino)carbonyl]-4-phenyl-5-(4-fluorophenyl)-1H-pyrrol-1-yl]htanoic acid]calcium salt; Atorvastatin; 3S,5S-Atorvastatin Calcium; Calcium bis{(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate}; Atorvastatin Calclum; delta-dihydroxy-2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-bet calci1h-pyrrole-1-htanoic acid; beta,delta-dihydroxy-2-(4-fluorophenyl)-5-(1-Methylethyl)-3-phenyl-4-((phenylaMino)carbonyl)-calciun salt(2:1); Atorvastatin Ca Hydrate; (3R,5R)-7-[2-(4-Fluorophenyl)-5-Isopropyl-3-Phenyl- 4-(Pheynylcbamoyl)Pyrrol-1-yl]-3,5–Dihydrohtanoic Acid, calcium salt; calciumsalt(2:1),(r-(r*,r*))-lethyl)-3-phenyl-4-((phenylamino)carbonyl); Atorvastatin Calcium Anhydrous; calcium bis{(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate}; ci-981; ATORVASTATINE CADIUM; [r-(r*, r*)]-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylaminocbonyl)-1h-pyrrol-1-yl]-3,5-dihydroxy-htanoic acid calcium salt; Tahor; (R,dR)-2-(4-Fluorophenyl)-,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-htanoic Acid Calcium; ATORVASTATIN CA; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt, (βR,δR)- (2:1); Alorvastin calcium; delta-dihydroxy-2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-betcalci1h-pyrrole-1-htanoicaci; ATORVASTATIN CALCIUM; MFCD03613598; pd134298-38a; Atorvastatin calciuM salt trihydrate; Calcium (bR,dR)-2-(p-fluorophenyl)-b,d-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoate; EINECS 200-659-6; Liprimar; (3R, 5R)-7-[2-(4-Fluorophenyl)-5-Isopropyl-3-Phenyl-4-(PheynylcbaMoyl) Pyrrol-1-yl]-3, 5 -Dihydrohtanoic Acid, calciuM salt (2:1) Trihydrate (crystal); Atorvastatin CalciuM API; Atovastadine CA; YM-548; Atorvastatin Calcium; (3R ,5R )-7-[2-(4-Fluorophenyl)-5-Isopropyl-3-Phenyl-4-(Pheynylcbamoyl) Pyrrol-1-yl]-3 ,5 -Dihydrohtanoic Acid, calcium salt (2:1) Trihydrate; 1H-Pyrrole-1-htanoic acid, 2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (.beta.R,.delta.R); Atorvastatin c; Atorvastatin aMorphous; Atrovastatin calcium; 1H-Pyrrole-1-htanoicacid,2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-,calciumsalt(2:1),(βR,δR)

物化性质

• 熔点: 176-178°C
• 分子式: C₆₆H₆₈CaF₂N₄O₁₀
• 分子量: 1155.342
• 精确质量: 1154.453003
• 外观性状: 白色 粉末
• 储存条件: Store at +4°C

安全

• 危害码 (欧洲): Xn,T,F
• 风险声明 (欧洲): 20/21/22-36/37/38-39/23/24/25-23/24/25-11
• 安全声明 (欧洲): 26-36-45-36/37-16-7